SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Core Viewpoint - SELLAS Life Sciences Group, Inc. is set to present preclinical efficacy data of SLS009 (tambiciclib) in ASXL1 mutated colorectal cancer at the 2025 ASCO Annual Meeting, highlighting its potential in cancer treatment [1][2]. Group 1: Product Development - SLS009 is currently undergoing a Phase 2 open-label, single-arm, multi-center study to evaluate its safety, tolerability, and efficacy in combination with venetoclax and azacitidine for AML patients with ASXL1 mutations [3]. - The study aims to identify biomarkers for the target patient population and enrich further trials [3]. - Initial clinical safety and efficacy data for SLS009 have been made available [3]. Group 2: Company Overview - SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for various cancer indications [4]. - The lead product candidate, GPS, targets the WT1 protein and has potential applications in both monotherapy and combination therapy for hematologic malignancies and solid tumors [4]. - SLS009 is positioned as a potentially first and best-in-class small molecule CDK9 inhibitor, showing a high response rate in AML patients with unfavorable prognostic factors, including ASXL1 mutations [4].